Abstract 3400
Background
Dermatologic toxicities related to radiotherapy treatments affect substantially the patient’s quality of life. It is well stated that the causes are closely related to the radiotherapy treatment technique and to the individual genetic variation factors. More specifically, the received by each skin point is suggested as one of the most important among those causes. But there are still no studies proving this correlation as the skin radiation dose is only assessed within a 15% uncertainty using the current feasible procedures in a common department. On the contrary, we would expect a good correlation, even more, stating a skin-toxicities predicting method by assessing the skin dose using a feasible 5% uncertainty procedure.
Methods
Prospective transversal study of breast cancer patients receiving normofractionated external radiation therapy, without bolus compensator. This study uses a non-invasive innovative method to obtain accurate skin radiation doses based in a Software as a Service and radiochromic films.The prescribed dose, the dose report from the Treatment Planning System as well as its class and version, the irradiated volume and measured skin dose and extension by means of this innovative method at fractions 1, 2, 3, 15, 25 and end of treatment will be collected and correlated to acute skin toxicities of the patients. This will be performed using the Radiation Therapy Group gradation during the nurse visit ongoing- and post-treatment till 90 days since its ending.
Results
This study will state a skin radiation dose – toxicity relationship for breast cancer patients as a result of a Pearson correlation coefficient analysis for each pair of variables.
Conclusions
The most common action in a nurse care plan is to treat signs and symptoms of the dermatologic toxicities but its causes are excluded, mainly due to a lack of knowledge. This study tries to formally state the skin radiation dose – toxicities relationship and, furthermore, the theoretical bases to determine and predict the skin radiation toxicities grade for each treatment. Even more, this will become a useful tool to improve the treatment success probability as well as empowering nursing for designing more accurate patient-specific radiotherapy care plans.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract
3988 - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.
Presenter: Sara Santagata
Session: Poster Display session 3
Resources:
Abstract